Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status

Lu F, Ahmed AA, Zhang S, Raman VK, Patel SS, Vargas JD, Fonarow GC, Heidenreich PA, Cleland JGF, Anker SD, Böhm M, Metra M, Zile[...]

Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes

Andrade-Bucknor S, Barforoshi S, Le DE, Lyubarova R, Chung J. Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis[...]

Transthyretin Cardiac Amyloidosis in an Older Athlete

O'Brien D, Reiss RA. Transthyretin Cardiac Amyloidosis in an Older Athlete. Cureus. 2026 Jun 29;18(6):e111747. doi: 10.7759/cureus.111747. PMID: 42534173; PMCID: PMC13419844.